• 1
    Boisseau M, Guichard S, Canal P, Bugat R. Irinotecan (CPT-11): current status and perspectives. Exp Opin Invest Drugs. 1996; 5: 613626.
  • 2
    Houghton PJ, Cheshire PJ, Hallman JD, et al. Efficacy of topoisomerase I inhibitors, topotecan and irinotecan, administered at low dose levels in protracted schedules to mice bearing xenografts of human tumors. Cancer Chemother Pharmacol. 1995; 36: 393403.
  • 3
    Vassal G, Terrier-Lacombe MJ, Bissery MC, et al. Therapeutic activity of CPT-11, a DNA-topoisomerase I inhibitor, against peripheral primitive neuroectodermal tumor and neuroblastoma xenografts. Br J Cancer. 1996; 74: 537545.
  • 4
    Furman WL, Stewart CF, Poquette CA, et al. Direct translation of a protracted irinotecan schedule from a xenograft model to a phase I trial in children. J Clin Oncol. 1999; 17: 18151824.
  • 5
    Cosetti M, Wexler LH, Calleja E, et al. Irinotecan for pediatric solid tumors: the Memorial Sloan-Kettering experience. J Pediatr Hematol Oncol. 2002; 24: 101105.
  • 6
    Blaney S, Berg SL, Pratt C et al. A phase I study of irinotecan in pediatric patients: a Pediatric Oncology Group study. Clin Cancer Res. 2001; 7: 3237.
  • 7
    Vassal G, Doz F, Frappaz D, et al. A phase I study of irinotecan as a 3-week schedule in children with refractory or recurrent solid tumors. J Clin Oncol. 2003; 21: 38443852.
  • 8
    Blaney SM, Needle MN, Gillespie A, et al. Phase II trial of topotecan administered as 72-hour continuous infusion in children with refractory solid tumors: a collaborative Pediatric Branch, National Cancer Institute, and Children's Cancer Group Study. Clin Cancer Res. 1998; 4: 357360.
  • 9
    Wagner LM, Crews KR, Iacono LC, et al. Phase I trial of temozolamide and protracted irinotecan in pediatric patients with refractory solid tumors. Clin Cancer Res. 2004; 10: 840848.
  • 10
    Rosoff PM, Bayliff S. Successful clinical response to irinotecan in desmoplastic round blue cell tumor. Med Pediatr Oncol. 1999; 33: 500503.